Zimhi FDA Approval Status
Last updated by Judith Stewart, BPharm on May 20, 2020.
FDA Approved: No
Brand name: Zimhi
Generic name: naloxone hydrochloride
Dosage form: Injection
Company: Adamis Pharmaceuticals Corporation
Treatment for: Opioid Overdose
Zimhi (naloxone hydrochloride) is a high-dose formulation of the approved opioid antagonist naloxone in development for the treatment of opioid overdose.
Development Timeline for Zimhi
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.